Home > Insider Trading > Filing (0000899243-21-036597)

Filing Details

Accession Number:: 0000899243-21-036597
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-20 17:00:26
Reporting Period:: 2021-09-16

Accepted Time:: 2021-09-20 17:00:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679082	Myovant Sciences Ltd.	MYOV	()	M0

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1446601	Dainippon Sumitomo Pharma Co Ltd	6-8 Doshomachi 2-Chome Chuo-Ku, Osaka M0 541-0045	No	No	Yes	No
1798244	Ltd. Biopharma Sumitovant	11-12 St. James'S Square Suite 1 3Rd Floor London X0 SW1Y 4LB	No	No	Yes	No
1798550	Sumitomo Chemical Co., Ltd.	27-1, Shinkawa 2-Chome Chuo-Ku, Tokyo M0 104-8260	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-09-16	50,000	$21.75	49,678,522	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2021-09-17	37,913	$22.79	49,716,435	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan").
The transaction was executed in multiple trades ranging from $21.24 to $22.19 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,678,522 shares of Common Stock following the acquisition on September 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
This acquisition of a total of 37,913 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
The transaction was executed in multiple trades ranging from $22.43 to $23.19 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Sumitovant directly owns 49,716,435 shares of Common Stock following the acquisition on September 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.